Collegium Pharmaceutical, Inc. Announces Initiation of Enrollment in Phase 3 Efficacy Study of Oxycodone DETERx® in Subjects With Moderate to Severe Chronic Lower Back Pain
8/29/2012 10:18:47 AM
CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx® (COL-003). This study is a randomized withdrawal, double-blind, placebo-controlled, enriched-enrollment, parallel-group, multicenter, 12-week clinical study in subjects with moderate-to-severe chronic lower back pain. The study is designed to compare the safety, efficacy and tolerability of Oxycodone DETERx® vs. placebo.
comments powered by